Carlsmed Inc Dossier - Source-backed chat

Carlsmed Inc

CARLNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.61

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $13.76Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $375.7M

Enterprise Value $318.3M

Shares Outstanding 27.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Carlsmed, Inc. is a high-growth medical technology pioneer transforming the spine surgery market through its AI-enabled personalized aprevo platform. By replacing traditional, one-size-fits-all spinal implants with patient-specific, 3D-printed titanium devices, Carlsmed significantly improves clinical outcomes, including a documented 74% reduction in revision rates at two years. The company's capital-light, digital-first business model enables rapid scaling with high gross margins (77.1% in Q1 2026) and short production lead times (six business days). With the recent FDA 510(k) clearance and CMS NTAP reimbursement approval for its cervical system, Carlsmed is well-positioned to capture a substantial share of the $13.4 billion addressable U.S. spine fusion market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$18.60

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The commercial rollout of the cervical system faces operational delays or slower-than-expected hospital formulary approvals. Intense competition from established spine surgery giants (e.g., Medtronic, Stryker, Globus Medical) limits market share gains. Elevated sales and marketing expenses persist, leading to a faster cash burn rate and requiring dilutive capital raises before reaching cash flow breakeven.

Base CaseCentral scenario

Carlsmed successfully executes the U.S. commercial launch of its aprevo cervical system in 2026, supported by the newly granted CMS NTAP reimbursement. Active surgeon adoption grows steadily, driving full-year 2026 revenues to the upper end of the guided $72 million to $77 million range (representing ~48% YoY growth). Gross margins remain stable above 75%, and operating leverage begins to narrow net losses, validating the scalability of the digital-first production model.

Bull CaseUpside scenario

Carlsmed's bull case centers on its highly disruptive, AI-enabled aprevo® platform, which designs and 3D-prints patient-specific spinal implants. This personalized approach has demonstrated a 74% reduction in revision surgery rates at two years compared to conventional stock implants, addressing a major pain point in a combined $24 billion lumbar and cervical fusion market. Growth is further accelerated by the commercial launch of its cervical fusion platform, supported by CMS New Technology Add-On Payment (NTAP) reimbursement of up to $21,125 per case starting in late 2025, and a strong cash position of $97.1 million as of Q1 2026 to fund commercial scaling.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly Differentiated Technology: The aprevo platform leverages proprietary AI and 3D printing to deliver level-specific, patient-matched implants in under six business days, offering a superior alternative to stock implants.
Strong Clinical Validation: Published data in the Global Spine Journal demonstrates a 74% reduction in revision rates at two years for aprevo lumbar patients compared to traditional implants.
Favorable Reimbursement Tailwinds: CMS granted New Technology Add-On Payment (NTAP) reimbursement for cervical fusion procedures using aprevo, lowering financial barriers for hospital adoption.
Capital-Light, High-Margin Model: Unlike traditional MedTech firms, Carlsmed scales without massive upfront inventory or instrument set investments, yielding exceptional gross margins of 77.1%.

Key Investment Risks

Commercial Execution Risk: Success depends heavily on the commercial rollout of the newly cleared cervical system and expanding the active surgeon user base.
Intense Competition: Carlsmed competes against well-capitalized, established industry giants with deep hospital relationships and broad product portfolios.
Continued Net Losses: The company remains unprofitable ($8.7 million net loss in Q1 2026) as it heavily invests in R&D and sales expansion, though backed by $97.1 million in cash and investments.

Thesis Invalidation Triggers

A significant slowdown in year-over-year revenue growth below 30%.
Failure of the cervical system commercial launch to gain meaningful traction in 2026.
Gross margins deteriorating below 70% due to pricing pressure or manufacturing inefficiencies.
Unexpected regulatory hurdles or safety concerns leading to product recalls or usage restrictions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.